HLB Group to Deliver 'Plenary Oral Presentation' at AACR 2026... Unveils Four Research Achievements
HLB Group announced that it will present four research achievements at the American Association for Cancer Research (AACR 2026), the world’s largest academic conference for cancer research, which will be held in San Diego, United States, starting April 17 (local time).
According to the official AACR program, three abstracts by Verrismo Therapeutics, a subsidiary of HLB Innovation, and one abstract by Elevar Therapeutics, a subsidiary of HLB, have been listed.
Interim results from the Phase 1 (STAR-101) clinical trial of Verrismo’s chimeric antigen receptor T-cell (CAR-T) therapy ‘SynKIR-110’ for solid tumors have been selected for an oral presentation. Notably, this study has been included in the plenary session, where only research with significant meaning and impact is carefully chosen, thereby demonstrating both the clinical value of the study and its high visibility at this global academic event.
Preclinical results for the CAR-T therapy ‘SynKIR-310’ targeting hematologic cancers have also been selected for a poster presentation. The study will present data showing that SynKIR-310 demonstrated superior antitumor efficacy compared to conventional CD3-based CAR-T cells in a B-cell non-Hodgkin lymphoma xenograft mouse model, and that the initial clinical signals support the potential for future clinical development.
Preclinical data on an EGFR-targeted KIR-CAR for glioblastoma, produced in collaboration with researchers from the University of Pennsylvania, will also be presented as a poster. This study contains preclinical results showing meaningful antitumor effects in resistant glioblastoma models, overcoming the limitations of existing CAR-T therapies. The differentiated and expandable nature of Verrismo’s proprietary ‘KIR-CAR’ platform technology has drawn particular attention. Elevar Therapeutics will also release a poster presentation comparing the high selectivity of its FGFR2-targeted anticancer drug ‘Lirafugratinib’ with existing pan-FGFR inhibitors.
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "500,000 Won Fine If You Don't Buy a Fire Extinguisher"... 'Fire Official Impersonation Phone Scams' on the Rise
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
An HLB Group representative stated, “This AACR 2026 presentation is an important milestone demonstrating that the competitiveness of our major pipelines, including SynKIR-based cell therapies and FGFR2-targeted anticancer drugs, is being substantiated through clinical and preclinical data.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
